financetom
Business
financetom
/
Business
/
ReposiTrak Slated to Join Russell 3000 After Yearly Reconstitution Takes Effect July 1
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ReposiTrak Slated to Join Russell 3000 After Yearly Reconstitution Takes Effect July 1
May 30, 2024 9:25 AM

12:05 PM EDT, 05/30/2024 (MT Newswires) -- ReposiTrak ( TRAK ) Thursday said it is expecting to be added to the Russell 3000 index July 1 following the conclusion of the 2024 Russell US Indexes annual reconstitution.

Membership in the index, which remains in place for one year, also means inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes, the company said.

ReposiTrak ( TRAK ) provides business customers with tools to monitor their regulatory compliance.

Price: 16.51, Change: +0.05, Percent Change: +0.30

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer
Sector Update: Consumer
Aug 2, 2024
08:48 AM EDT, 08/02/2024 (MT Newswires) -- Consumer stocks were mixed premarket Friday as the Consumer Staples Select Sector SPDR Fund (XLP) was up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) fell by 3.6% recently. Church & Dwight ( CHD ) shares fell by more than 4% after the consumer goods company said it expects Q3 adjusted...
Plains GP Holdings Q2 Net Income Falls, Revenue Rises
Plains GP Holdings Q2 Net Income Falls, Revenue Rises
Aug 2, 2024
08:51 AM EDT, 08/02/2024 (MT Newswires) -- Plains GP Holdings ( PAGP ) reported Q2 net income Friday of $0.20 per diluted share, down from $0.25 a year earlier. Four analysts polled by Capital IQ expected $0.20. Revenue for the quarter ended June 30 was $12.93 billion, up from $11.6 billion a year earlier. Three analysts surveyed by Capital IQ...
Atmus Filtration Q2 Adjusted Earnings, Sales Rise; 2024 Outlook Updated -- Shares Gain Pre-Bell
Atmus Filtration Q2 Adjusted Earnings, Sales Rise; 2024 Outlook Updated -- Shares Gain Pre-Bell
Aug 2, 2024
08:51 AM EDT, 08/02/2024 (MT Newswires) -- Atmus Filtration Technologies ( ATMU ) reported Q2 adjusted earnings Friday of $0.71 per diluted share, up from $0.63 a year earlier. Analysts polled by Capital IQ expected $0.58. Net sales for the quarter ended June 30 were $432.6 million, up from $413.6 million a year earlier. Analysts surveyed by Capital IQ expected...
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Aug 2, 2024
Thursday, the FDA approved Adaptimmune Therapeutics ( ADAP ) plc’s Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma, a rare type of cancer that tends to occur near large joints, mainly the knees. The approval covers patients who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen. This indication is approved under...
Copyright 2023-2026 - www.financetom.com All Rights Reserved